International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia.
| Title: | International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia. |
|---|---|
| Authors: | Aliberti S; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Respiratory Unit and Cystic Fibrosis Adult Center, and University of Milan, Department of Pathophysiology and Transplantation, Milan Italy.; Cook GS; Division of Pulmonary Diseases & Critical Care Medicine, The University of Texas Health Science Centre at San Antonio, San Antonio, TX, USA.; Babu BL; Division of Pulmonary Diseases & Critical Care Medicine, The University of Texas Health Science Centre at San Antonio, San Antonio, TX, USA; Division of Pulmonary Diseases & Critical Care Medicine, South Texas Veterans Health Care System, 7400 Merton Minter Boulevard, San Antonio, TX 78229, USA.; Reyes LF; Department of microbiology, Universidad de la Sabana, Bogota, Colombia.; H Rodriguez A; Critical Care Medicine, Hospital Universitari Joan XXIII, Rovira & Virgili University and CIBERes (Biomedical Research Network of Respiratory disease), Tarragona, Spain.; Sanz F; Pulmonology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain.; Soni NJ; Division of Pulmonary Diseases & Critical Care Medicine, The University of Texas Health Science Centre at San Antonio, San Antonio, TX, USA; Division of Pulmonary Diseases & Critical Care Medicine, South Texas Veterans Health Care System, 7400 Merton Minter Boulevard, San Antonio, TX 78229, USA.; Anzueto A; Division of Pulmonary Diseases & Critical Care Medicine, The University of Texas Health Science Centre at San Antonio, San Antonio, TX, USA; Division of Pulmonary Diseases & Critical Care Medicine, South Texas Veterans Health Care System, 7400 Merton Minter Boulevard, San Antonio, TX 78229, USA.; Faverio P; Cardio-Thoracic-Vascular Department, University of Milan Bicocca, Respiratory Unit, San Gerardo Hospital, ASST di Monza, Monza, Italy.; Sadud RF; Section of Hospital Medicine, Medical College of Wisconsin, WI, USA.; Muhammad I; Section of Pulmonary and Critical Care Medicine, Department of Medicine, Aga Khan University, Karachi-74800, Pakistan.; Prat C; Microbiology Department, Hospital Universitari Germans Trias i Pujol. Institut d'Investigació Germans Trias i Pujol, Badalona, Spain. Universitat Autònoma de Barcelona. CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Spain.; Vendrell E; Intensive Care Medicine, Hospital de Mataró, Spain.; Neves J; Serviço de Medicina, Centro Hospitalar do Porto, Largo Prof. Abel Salazar, 4099-001 Porto, Portugal.; Kaimakamis E; Intensive Care Unit, 'G. Papanikolaou' General Hospital of Thessaloniki, Greece.; Feneley A; University Hospitals of Leicester NHS Trust, Leicester, UK.; Swarnakar R; Getwell Hospital & Research Institute, Dhantoli, Nagpur, India.; Franzetti F; Department of Biomedical and Clinical Sciences, Division of Infectious Diseases, Luigi Sacco Hospital, Università degli Studi di Milano, Milan, Italy.; Carugati M; Department of Biomedical and Clinical Sciences, Division of Infectious Diseases, Luigi Sacco Hospital, Università degli Studi di Milano, Milan, Italy.; Morosi M; Department of Biomedical and Clinical Sciences, Division of Infectious Diseases, Luigi Sacco Hospital, Università degli Studi di Milano, Milan, Italy.; Monge E; Department of Biomedical and Clinical Sciences, Division of Infectious Diseases, Luigi Sacco Hospital, Università degli Studi di Milano, Milan, Italy.; Restrepo MI; Division of Pulmonary Diseases & Critical Care Medicine, The University of Texas Health Science Centre at San Antonio, San Antonio, TX, USA; Division of Pulmonary Diseases & Critical Care Medicine, South Texas Veterans Health Care System, 7400 Merton Minter Boulevard, San Antonio, TX 78229, USA. Electronic address: restrepom@uthscsa.edu. |
| Corporate Authors: | GLIMP investigators |
| Source: | The Journal of infection [J Infect] 2019 Oct; Vol. 79 (4), pp. 300-311. Date of Electronic Publication: 2019 Jul 09. |
| Publication Type: | Journal Article; Research Support, U.S. Gov't, Non-P.H.S. |
| Language: | English |
| Journal Info: | Publisher: W.B. Saunders Country of Publication: England NLM ID: 7908424 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2742 (Electronic) Linking ISSN: 01634453 NLM ISO Abbreviation: J Infect Subsets: MEDLINE |
| Imprint Name(s): | Publication: Kent, UK : W.B. Saunders; Original Publication: London, New York, Academic Press. |
| MeSH Terms: | Drug Resistance, Bacterial* ; Global Health*; Anti-Bacterial Agents/*pharmacology ; Pneumonia, Pneumococcal/*epidemiology ; Streptococcus pneumoniae/*drug effects; Community-Acquired Infections/epidemiology ; Community-Acquired Infections/microbiology ; Hospitalization/statistics & numerical data ; Pneumonia, Pneumococcal/microbiology ; Aged ; Aged, 80 and over ; Cost of Illness ; Female ; Humans ; Internationality ; Male ; Middle Aged ; Prevalence ; Risk Factors |
| Abstract: | Objective: Streptococcus pneumoniae is the most frequent bacterial pathogen isolated in subjects with Community-acquired pneumonia (CAP) worldwide. Limited data are available regarding the current global burden and risk factors associated with drug-resistant Streptococcus pneumoniae (DRSP) in CAP subjects. We assessed the multinational prevalence and risk factors for DRSP-CAP in a multinational point-prevalence study.; Design: The prevalence of DRSP-CAP was assessed by identification of DRSP in blood or respiratory samples among adults hospitalized with CAP in 54 countries. Prevalence and risk factors were compared among subjects that had microbiological testing and antibiotic susceptibility data. Multivariate logistic regressions were used to identify risk factors independently associated with DRSP-CAP.; Results: 3,193 subjects were included in the study. The global prevalence of DRSP-CAP was 1.3% and continental prevalence rates were 7.0% in Africa, 1.2% in Asia, and 1.0% in South America, Europe, and North America, respectively. Macrolide resistance was most frequently identified in subjects with DRSP-CAP (0.6%) followed by penicillin resistance (0.5%). Subjects in Africa were more likely to have DRSP-CAP (OR: 7.6; 95%CI: 3.34-15.35, p |
| Contributed Indexing: | Keywords: Global burden of disease; Microbial drug resistant; Pneumococcal infection; Pneumonia |
| Substance Nomenclature: | 0 (Anti-Bacterial Agents) |
| Entry Date(s): | Date Created: 20190713 Date Completed: 20200724 Latest Revision: 20200724 |
| Update Code: | 20260130 |
| DOI: | 10.1016/j.jinf.2019.07.004 |
| PMID: | 31299410 |
| Database: | MEDLINE |
Journal Article; Research Support, U.S. Gov't, Non-P.H.S.